Perioperative Keytruda-Padcev for MIBC approved regardless of cisplatin eligibility ...

Adults diagnosed with muscle-invasive bladder cancer gained a new treatment option on July 10, 2026, when the FDA cleared the ...

The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. | The ...

Chemotherapy used to target and kill bladder cancer cells may trigger an inflammatory response that ultimately may make the cancer more resistant to treatment, according to new research from ...

Neoadjuvant cisplatin-based chemotherapy plus chemoradiotherapy offers a safe, effective bladder-sparing approach with promising long-term outcomes in nonmetastatic MIBC. Median disease-free survival ...

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced ...

Cisplatin-based NAC and AMVAC improved two-year MFS in MIBC patients, with a 72.9% overall MFS rate. 17% of all patients and 48% in the AS group avoided cystectomy without metastatic disease. Severe ...

About one quarter of patients with muscle-invasive bladder cancer (MIBC) may be treated and derive a benefit with the current standard chemotherapy. To better understand why some tumors resist ...

Chemotherapy used to target and kill bladder cancer cells may trigger an inflammatory response that ultimately may make the cancer more resistant to treatment, according to new research from ...

S.M. Gilbert is a fellow in Urologic Oncology in the Department of Urology atthe University of Michigan, MI. C.T. Lee is an Associate Professor of Urologyat the University of Michigan, MI, USA, where ...

About one quarter of patients with muscle-invasive bladder cancer (MIBC) may be treated and derive a benefit with the current standard chemotherapy. To better understand why some tumors resist ...